

US Clinical Data Highlight CERAMENT® G in Infection Prevention for Trauma Patients

BONESUPPORT™, a leader in orthobiologics for the management of bone injuries, today announces the publication of the first US clinical case series describing a surgical technique and early outcomes using CERAMENT G during intramedullary nailing in patients with open fractures. Published in *OTA International*, the study offers practical insights for surgeons treating Gustilo–Anderson Type II and III long-bone fractures.

The single-center case series from HCA Florida Kendall Hospital, a Level-1 trauma center, reports on nine patients with open tibia, femur, or humerus fractures managed with CERAMENT G delivered through the Flow-FX™ 2-CAN® device to support augmentation of an intramedullary nail and targeted gentamicin elution within the intramedullary canal. At an average follow-up of 9.1 months, all patients achieved fracture union, with no fracture-related infections, amputations, or reoperations for infection.

The authors conclude that augmentation of intramedullary nails with CERAMENT G may offer a time-efficient, technically straightforward method for local antibiotic prophylaxis in high-risk open fractures.

“This publication adds to the growing US clinical evidence base for CERAMENT G. Despite the small series, the results indicate that CERAMENT G provides reliable local antibiotic elution with the potential to help prevent infection, while also supporting bone healing when used for intramedullary nail augmentation in the management of complex open fractures,” said Torbjörn Sköld, CEO of BONESUPPORT.

For more information contact:

BONESUPPORT AB
Torbjörn Sköld, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

Press Release
06 March 2026 14:10:00 CET



About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to 1,175 msek in 2025. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

[US Clinical Data Highlight CERAMENT® G in Infection Prevention for Trauma Patients](#)